Fig 1: Inferred CNA profiles from snRNA-Seq in diverse tumors.Chromosomal amplification (red) and deletion (blue) inferred in each chromosomal position (columns) across the single nuclei (rows) from three MBC samples (a–f), one ovarian cancer sample (g-i) and one sarcoma sample (j, k). Top: reference nuclei not expected to contain CNA in this cancer type. Bottom: nuclei tested for CNA relative to the reference nuclei. Color bar: assigned cell type signature for each nucleus. n = 1 sample per protocol and number of nuclei (k) per sample: MBC HTAPP-963-SMP-4741—9,857 (CST), 7,260 (TST); MBC HTAPP-394-SMP-1561—6,948 (CST), 8,058 (NST); MBC HTAPP-589-SMP-2851—7,858 (CST), 8,373 (TST); ovarian HTAPP-316-SMP-991—9,026 (CST), 5,970 (NST), 10,493 (TST); sarcoma HTAPP-951-SMP-4652—7,858 (CST), 4,458 (TST).
from Cell Signaling Technology for PTMScan ® Phospho-MAPK/CDK Substrate Motif (PXS*P and S*PXK/R) Kit